Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma

por Luke, Jason J.
Publicado 2019

Considering adjuvant therapy for stage II melanoma

por Poklepovic, Andrew S., Luke, Jason J.
Publicado 2019

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

por Luke, Jason J, Ott, Patrick A
Publicado 2014

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

por Luke, Jason J., Ott, Patrick A.
Publicado 2015

Improving therapy in metastatic uveal melanoma by understanding prior failures

por Olson, Daniel J., Luke, Jason J.
Publicado 2020

Toll-Like Receptor 9 Agonists in Cancer

por Karapetyan, Lilit, Luke, Jason J, Davar, Diwakar
Publicado 2020

Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types

por Bao, Riyue, Stapor, Daniel, Luke, Jason J.
Publicado 2020

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

por Trojaniello, Claudia, Luke, Jason J., Ascierto, Paolo A.
Publicado 2021

Targeting Cbl-b in cancer immunotherapy

por Augustin, Ryan C., Bao, Riyue, Luke, Jason J.
Publicado 2023

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

por Labadie, Brian W., Balar, Arjun V., Luke, Jason J.
Publicado 2021

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a ran...

por Luke, Jason J., Zha, Yuanyuan, Matijevich, Karen, Gajewski, Thomas F.
Publicado 2016

High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery

por Zielinski, Jessica M., Luke, Jason J., Guglietta, Silvia, Krieg, Carsten
Publicado 2021

Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer

por Sweis, Randy F, Spranger, Stefani, Luke, Jason J, Gajewski, Thomas F
Publicado 2015

The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors

por Luke, Jason J, Spranger, Stefani, Bao, Riyue, Andrade, Jorge, Gajewski, Thomas F
Publicado 2015

The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent

por Jutzy, Jessica M. S., Lemons, Jeffrey M., Luke, Jason J., Chmura, Steven J.
Publicado 2018

STING Agonists as Cancer Therapeutics

por Amouzegar, Afsaneh, Chelvanambi, Manoj, Filderman, Jessica N., Storkus, Walter J., Luke, Jason J.
Publicado 2021

Editorial: Mechanisms of Lymphocyte Exclusion in the Tumor Microenvironment

por van de Ven, Rieneke, Bifulco, Carlo B., Luke, Jason J., Church, Sarah E.
Publicado 2022

Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies

por Frohne, Christopher C., Llano, Ernesto M., Perkovic, Ashley, Cohen, Russell D., Luke, Jason J.
Publicado 2019

Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac Allograft

por Goodman, Amy E., Karapetyan, Lilit, Pugliano-Mauro, Melissa, Levenson, Joshua E., Luke, Jason J.
Publicado 2021

Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy

por Augustin, Ryan C., Leone, Robert D., Naing, Aung, Fong, Lawrence, Bao, Riyue, Luke, Jason J.
Publicado 2022